CompletedPhase 2ACTRN12606000281594

Infant fish oil study

The immunomodulatory effects of omega-3 polyunsaturated fatty acids : role in allergy prevention

Sponsor

Prof Susan Prescott

Enrollment

360 participants

Start Date

Jun 1, 2005

Study Type

Interventional

Conditions

Allergic disease

Summary

In this study we will compare the effects of fish oil (n=165) or placebo (n=165) in early infancy (from 0-6 months of age) on the risk of developing allergic sensitisation or allergic disease in early childhood. Both study groups will include children deemed to be at high risk of allergic disease (based on maternal allergy history).

Eligibility

Sex: Both males and females

Plain Language Summary

Simplified for easier understanding

This study investigates Infant fish oil study. It is looking for both men and women who have 1) maternal asthma or hayfever, and atopy confirmed by skin testing (to common allergens); and 2) maternal age. People who are pregnant or breastfeeding individuals cannot take part. If you are interested, you may need to attend study visits and follow the research team's instructions.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Children will be randomised to receive n-3 rich fish oil (280mg docosahexanoic acid [DHA]/day; 110mg eicosapentanoic acid [EPA]/day orally; Meg 3 Ocean Nutrition, Canada) daily for the first 6 months

Children will be randomised to receive n-3 rich fish oil (280mg docosahexanoic acid [DHA]/day; 110mg eicosapentanoic acid [EPA]/day orally; Meg 3 Ocean Nutrition, Canada) daily for the first 6 months of life. The capsules are identical in appearance. Peppermint flavour has been added to both fish oil and placebo capsules.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12606000281594

Related Trials

A Study to Find a Suitable Dose of Exl-111 for Further Research

NCT073567131 location

Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis

NCT073164651 location